Electrochemiluminescence. A technology evaluation and assay reformatting of the Stat6/P578 protein-peptide interaction.
Schweitzer
Robert H
RH
Novartis Pharmaceuticals Corporation, Summit, NJ, USA.
Abriola
Laura
L
D050976:Basic-Leucine Zipper Transcription Factors; D001710:Biotin; D002614:Chelating Agents; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases / Q000032:analysis / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000032:analysis / Q000378:metabolism; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004563:Electrochemistry; D018189:Immunomagnetic Separation; D066298:In Vitro Techniques; D008163:Luminescent Measurements; D008967:Molecular Biology / Q000379:methods; D010748:Phosphopeptides / Q000032:analysis* / Q000378:metabolism; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis / Q000378:metabolism; D012428:Ruthenium; D050800:STAT6 Transcription Factor; D015534:Trans-Activators / Q000032:analysis* / Q000378:metabolism; D014157:Transcription Factors
D050976:Basic-Leucine Zipper Transcription Factors; D002614:Chelating Agents; D004268:DNA-Binding Proteins; C067850:Myc associated factor X; D010748:Phosphopeptides; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D050800:STAT6 Transcription Factor; D015534:Trans-Activators; D014157:Transcription Factors; D001710:Biotin; D012428:Ruthenium; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases